Since we found that both TGFβ1 and TGFβ3 isoform expression were detectable at 11 days post tumor implantation, a time point at which the B16F10 tumors are palpable and well established, we began treatment with isoform-specific anti-TGFβ therapy at this time. This evidence concerns the gene TGFB3 and neoplasm.